Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chiron, Roche Settle HCV/HIV Patent Dispute Via $115 Mil. Licensing Pact

This article was originally published in The Gray Sheet

Executive Summary

A licensing agreement struck between Chiron and Roche, announced Oct. 11, resolves patent litigation pending against Roche in the U.S. and overseas related to probe-based hepatitis C virus (HCV) and HIV clinical diagnostics while leaving intact complaints against Roche in Germany related to antibody-based HCV immunoassay diagnostic patents.
Advertisement

Related Content

Gen-Probe Spin-Off Planned To Avoid Chugai/Roche Diagnostic Overlap
Gen-Probe Spin-Off Planned To Avoid Chugai/Roche Diagnostic Overlap
Bayer HCV/HIV Lab Tests Anticipated In 2002 Via Chiron/Ortho License
Bayer HCV/HIV Lab Tests Anticipated In 2002 Via Chiron/Ortho License
Roche
Roche
Roche Amplicor, Cobas HCV RNA Tests Approvable With Conditions - Panel
Roche Amplicor, Cobas HCV RNA Tests Approvable With Conditions - Panel
Bayer's $1.1 Bil. Chiron Diagnostics Buy Adds Blood Gas Analyzer Line
Advertisement
UsernamePublicRestriction

Register

MT013982

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel